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Actuality. Imbalance between pro-inflammatory 
and anti-inflammatory cytokines influences the immun-
opathogenesis of viral B and C hepatitis. A number of stud-
ies indicate that the plasmatic concentration of IL 1 varies 
in case of viral hepatitis it getting involved into the viral 
clearance. For example, in the study of Haizhen Zhu and 
Chen Liu (Florida, 2003) the IL-1 is shown to have a role in 
the effective inhibition of VHC through the inhibition of 
the VHC subgenomic replication and reduction of the vi-
ral protein expression. These authors suggest the idea that 
IL 1 has a direct antiviral effect. IL -1 has a similar effect to 
IL -4 in case of acceleration of the B -lymphocytes prolifer-
ation and production of antibodies. It induces production 
of proteins by hepatocytes in an acute inflammatory phase 
and influences SNC, favouring somnolence and anorexia. 
It increases creation of E2 prostaglandin and A2 phosphol-
ipase, which might lead to fever development. It contrib-
utes to the increase of other cytokines production, such 
as IL-6, IL-8, gamma-IFN and TNF. The suppressor factor 
IL10 is produced mainly by the T- lymphocyte helper type 
2. In causes inhibition of the T-helper type 1 function and 
the monocytes, reducing production of immunocytokines 
(gamma IFN, IL-1, IL-8, TNF). It increases proliferation of 
B-lymphocytes and tissue basophiles. Thus, IL- 10 is one of 
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Summary
Introduction: T-cell immunoregulatory cytokines influence the persistence of hepatitis C and B virus (HCV, HBV) chronic infection and 
the extent of liver damage. Th1 cytokines positively correlate with hepatic inflammation in HBV and HCV chronic infection. The pro-
inflammatory cytokines are involved in viral clearance and in metabolic and viral hepatic diseases, respectively. The aim of this study 
is to evaluate the biochemical, haematological parameters and profile of Th1/Th2 cytokines in HCV and HBV hepatitis before and after 
treatment with BioR. Methods: The study included 42 patients with chronic viral hepatitis. Following the aim the establishment of the 
viral hepatitis aetiology it was decided to define the markers of the viral hepatitis, the antibodies antiHCV total, antiHCV IgM, HbsAg, 
antiHBs, antiHBcor total and IgM, as well as to identify the alcohol consumption through use of different questionnaires. Along with 
the evaluation of the liver status also the abdominal ecography and the hepatic gamma-scintigraphy or scanning of the liver has been 
performed. The immunoenzymatic assay has been used to study the interleukins 1, 10 and TNF-alpha. Patients included in the study 
have been administered the injection solution of BioR, 1.0 ml intramuscular, daily, during 10 days. Results: Our study has indicated 
that BioR causes a number of haematological actions in case of patients with HCV. Thus, patients with HCV show a real amelioration of 
haemoglobin (p<0.05), and of lymphocyte levels (p<0.05) compared to patients with HBV. In result of the application of a therapy with 
BioR an evident diminution of cytolysis (ALT, AST) takes place both in patients with HBV (p<0.05) and in the ones with HCV (p<0.05). 
This indicates the fact that BioR plays the role of a hepatic protector. It has been also proven that BioR reduces gamma GTP in patients 
with HCV (p<0.05) compared to patients with HBV (p>0.05), indicating to the occurrence of a disintoxication. This study has shown 
that a treatment with BioR brings about the stimulation of production of IL 10, TNF alpha in patients with HCV and HBV. We consider 
this action a key mechanism of this preparate with antiviral effect, and we recommend it for treatment of persons with viral hepatitis. 
Conclusions: This study indicates that the use of the BioR preparate in chronic viral B and C hepatitis is justified, given the fact that it 
acts as a hepatic protector, causes haematological regulation and has the disintoxication and immune-modulation effects. 
the most important cytokines with a regulatory function, 
the action of which causes inhibition of the T-lymphocy-
tary type 1 cellular response and stimulates the humoral 
response (T- lymphocytes type 2). It is an anti-inflamma-
tory cytokine. The Th1\Th2 disbalance plays an active role 
in the immunopathogenesis of chronic hepatitis. Studies 
carried out in this area indicate that the response of cyto-
toxic T lymphocytes is rather heterogenic in patients with 
chronic hepatitis.  In about 30 - 46% cases of chronic viral 
hepatitis the obtained response was evident. The response 
of cytotoxic T lymphocytes varies from person to person 
and is limited by the HLA spectrum, thus determining the 
viral epitopes presented in the immune system. 
TNF – alpha is produced by different cells: monocytes, 
macrophages, B- and T-lymphocyte. This is a pro inflam-
matory cytokine. It is characterised by rather varied effects, 
which depend, to a great extent, on its concentration. In 
small concentrations the TNF-alpha increases synthesis of 
adhesion molecules on the endothelial cells, thus allowing 
the neutrophils to adhere to the blood vessels at sites of 
inflammation. 
Among other effects are the activation of the respira-
tory system in neutrophils, stimulation of potential killer 
cells via phagocytosis, increase of lymphokines caused by 
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T-lymphocytes and stimulation of maturation of B-lym-
phocytes. In high concentrations TNF-alpha acts as a me-
diator able to favour the appearance of the septic juice in-
duced by endotoxins. In high concentrations the TNF-al-
pha is also called cachexia, given its property to inhibit the 
lipoprotein lipase of the adipose tissue and consequently to 
decrease the use of fat acids, thing that can induce develop-
ment of cachexia. The TNF-alpha favours cell necrosis of 
certain tumours as a result of development of intravascular 
thrombosis in the tumour tissue region. It also stimulates 
the production of IL1 and IL-6 and the expression of the 
class 1 MCH molecules. 
We decided to study the level of these cytokines in pa-
tients with HCVC and HCVB and also to assess the dy-
namics of their concentration following the treatment with 
BioR. This is a preparate already known in our country for 
its hepatic protection, anti oxidant and immunomodula-
tion effects. 
Goal of the study: investigation of the haematological, 
biochemical parameters and of the cytokine profile of pa-
tients suffering from chronic hepatic diseases, before and 
after the treatment with BioR, and of the cytokine profile of 
patients suffering from chronic hepatic diseases.
Objectives of the study:
1. assessment of the haematological indices of patients 
suffering from chronic hepatic diseases, before and 
after the treatment with BioR;
2. determination of the biochemical parameters (cy-
tolysis, cholestasis and hepatopriv syndromes) in pa-
tients suffering from chronic hepatic diseases, before 
and after the treatment with BioR;
3. evaluation of the interleukin pro- (IL-1) and anti- 
(IL-10) inflammatory profiles and of the TNF alpha 
values of patients suffering from chronic hepatic dis-
eases, before and after the treatment with BioR;
Materials and methods. The study included 42 de pa-
tients with chronic viral hepatitis. Following the aim the 
establishment of the viral hepatitis aetiology the markers 
of the viral hepatitis, the anti HCV antibodies, HBsAg, 
anti HBs, anti HBcor total were defined, and the alcohol 
consumption through use of different questionnaires was 
identified. Apart from the evaluation of the liver status, the 
abdominal ecography and the hepatic gamma-scintigraphy 
or scanning of the liver with Th has been also performed. 
In order to highlight the accompanying pathology and the 
complications of the hepatic disease, the esophagogastros-
copy, irigoscopie, duodenal evaluation with insemination 
of the bile investigations have been additionally carried 
out. The immunoenzymatic assay has been used to study 
the interleukins 1, 10 and TNF-Alpha. 
Patients included in the study have been administered 
(at the recommendation of the expert) the treatment with 
BioR in its injection solution, 1.0 ml, intramuscular, daily, 
during 10 days. BioR is a hepatoprotective agent, obtained 
via original targeted synthesis technologies of successive 
extraction from the cyanophilous algae biomass – Spir-
ulina platensis (Nordst) Geitl. BioR contains a large range 
of free amino acids, saturated and unsaturated fatty acids, 
polyzaharidies, all liposoluble and hydrosoluble vitamins 
and microelements. 
Obtained results. The clinical and paraclinical investi-
gations have indicated that 20 patients were VHB infected 
and 22 patients were VHC infected. The average age of 
patients was 37 ± 3.2 years old and women prevailed as 
gender (58%). Investigated patients originate from differ-
ent settlements of the Republic of Moldova where 71.4 % 
(30) patients come from the rural area and 28.9% (12) – 
from the urban area. Analysis of the length of the malady 
showed that 76.1% (32) patients suffer of this disease more 
than 5 years. The anamnestic investigation made possible 
the elucidation of a number of aspects dealing with the 
origin of this affection. Thus, 23.8% (10) of patients have 
mentioned the fact that they suffered an acute hepatitis, 
23.8% (10) of patients had haemotransfusions, 21.4% (9) 
supported surgery interventions and 11.9% (5) had tattoo 
or piercing. Depending on the infection phase, patients 
with the chronic viral B hepatitis have been placed into 
two categories: 57.8 (11) patients were in the replication 
phase and 42.2% (8) were patients in the integrative phase 
of the infection. 81.3% (18) patients with chronic C viral 
hepatitis fall into the reactivation category, while 18.7% (4) 
fall into the latent phase. Depending on the degree of acti-
vation of the pathologic hepatic process it was stated that 
61.8% (26) patients had minimal activation.
Evaluation of the clinical picture has indicated the pres-
ence of a diversity of symptoms. Nevertheless, forms with 
short clinic predominated. Table 1 shows basic symptoms 
of investigated patients.
Table 1. Characteristics of the patient clinic with 
chronic hepatitis included in the study
HBV (n=20) HCV (n=22)
dolor symptom 13 (68.4%) 12 (54.5%)
astenic symptom 15 (78.9%) 18 (81.8%)
dyspeptic symptom 11 (57.8%) 17 (77.2%)
icteric symptom 3 (15.7%) 4 (18.1%)
arthralgia 8 (42.10%) 11 (50%)
cutaneous pruritus 4 (21.05%) 4 (18.1%)
subfebrility 3 (15.7%) 4 (18.1%)
hepatomegaly 11 (57.8%) 16 (72.7%)
splenomegaly 6 (31.5%) 9 (40.9%)
The investigated patients (n=42) have been adminis-
tered BioR, 1.0 ml intramuscular, daily, during 10 days. 
Out of them, 10 days later, 32 patients have been subjected 
to a repeated control. In case of patients consulted for the 
second time the evolution of the clinic showed a decrease 
of the intensity of the asthenoneurotic and dyspeptic syn-
dromes and a reduction of the cutaneous pruritus. In spite 
of the fact that there was no evident improvement of the 
clinical symptomatology, the reason being the short treat-
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ment period, nevertheless a trend of improvement has 
been observed.
No substantial deviations of the haematological pa-
rameters from the accepted limits have been identified in 
case of patients with HBV (16), while in case of patients 
with HCV (16) an evident anaemic symptom has been 
recorded. Persons with chronic C hepatitis have shown a 
moderate lymphopenia versus admitted limits and versus 
patients with HBV. Administration of BioR implies certain 
modifications of the evolution of these indicators. Thus, 
there is practically no modification of the investigated hae-
matological parameters in patients with HBV, compared to 
a significant amelioration of both Hb (p<0.05) and lym-
phocytes (p<0.05) in persons with HCV. Consequently, 
agent BioR acts as an evident haematological modulator.
The biochemical analysis carried out within this study 
has shown the presence of cytolysis syndrome of different 
degrees in both patients with HBV and with HCV. 25% of 
patients have registered a moderate cytolysis, out of which 
62.5% are patients with HCV. Nevertheless, 31.2% of pa-
tients with chronic hepatitis tolerate the malady with nor-
mal transaminases.
Initially, ALT (mmol/l) in HCVC constituted 90.26±6.17 
and AST 69.6±6.44 (mmol/l), compared to 66.4±4.33 and 
AST 54.5±4.22 after the BioR therapy, while in HVB before 
the therapy ALT 82.6±11.11 and AST 63.2±3.46 have been 
registered, and after the therapy – ALT 59.3±4.61 and AST 
52.22±2.9, this indicating the fact that the agent has been 
included into the hepatocytary recovery processes.
Statistically veridical results have been obtained after 
the administration of the BioR agent, these including the 
evident reduction of cytolysis (ALT, AST) both in patients 
with HBV (p<0.05) and in the ones with HCV (p<0.05). 
Nevertheless, the value of these transaminases continues 
to remain high compared to the value registered in case of 
healthy persons, thing suggesting that the duration of the 
treatment might be too short.
It is interesting to mention that the investigation of 
the cholestatic syndrome has revealed the presence of a 
high level of gGTP in patients with HCV (2.5 times bigger 
than the normal level, in the average) versus patients with 
HBV (1.2 times more). Under the influence of the BioR 
therapy the level of gGTP has suffered a veridical decrease 
in patients with HCV (p<0.05) versus patients with HBV 
(p>0.05). Also the level of the cholesterol has undergone 
a veridical statistic regression in both groups of patients.
Trustworthy data have also been obtained with respect 
to the dynamics of the hepatopriv syndrome in patients 
with chronic B and C viral hepatitis subjected to a ther-
apy with BioR.  Thus, treatment with BioR has caused a 
veridical increase of albumin in both patients with HBV 
(p<0.05) and in patients with HCV (p<0.05).
The interrelation between the IL1 pro- inflammatory 
cytokines with the IL10 anti- inflammatory cytokines 
has also been investigated in this study. We think that the 
cytokine disbalance has a key role in the progress of the 
chronic hepatitis. Assessment of their concentration in the 
blood of patients with chronic hepatitis indirectly offers 
information about the functional activity of different types 
of immunocompetent cells, severity of the inflammation 
process and the latter’s transfer to a systemic level process. 
It also constitutes a forecast of the affection.
Table 2. Levels of IL1, IL10, TNF alpha in patients with 
HBV, HCV before and after the BioR therapy
  M m
p
  initial after therapy Initial
After 
therapy
IL1 0.53 0.57 0.128 0.139 p>0.05, t=0.2116   
IL10 7.23 9.03 1.008 1.29 p>0.05, t=1.0994   
TNF alpha 11.08 14.72 0.64 1.29 p<0.05, t=2.5277   
The following events have been observed in this study: 
a significantly reduced level of IL-1 in patients with HCVB, 
versus patients with HCVC, in conditions of a smaller IL-10 
concentration in HCVC, versus HCVB. This phenomenon 
suggests the idea that in case of HCVB the ante- inflamma-
tory processes predominate, while in HCVC predominates 
the pro- inflammatory process. Following the completion 
of the recommended therapeutic scheme, levels of inter-
leukins have been investigated, which has highlighted an 
increase of IL-1, non veridical in the two groups, and a ve-
ridical increase of IL-10 in both HCVB and HCVC. 
This result invokes the idea that BioR contributes to the 
regression of the inflammatory process, stimulating the 
concentration of the ante- inflammatory cytokines, in our 
case of IL-10.
Assessment of the TNF alpha level in patients includ-
ed in our study has indicated that the initial level of this 
cytokine falls in the same limits with the ones in patients 
with HCVB and HCVC. Following the administration of 
the BioR therapeutic scheme, a similar increase of the TNF 
alpha concentration has been identified in the two groups 
of patients.
Discussions: Studies in this area indicate the occur-
rence of a reduction of the T helpers’ concentration in 
blood in case of C hepatitis, followed by a decrease of IL-1 
and IL-2 levels. IL-1 is shown to have an important func-
tion in the regulation of the hepatic mechanism and it can 
also be responsible for the modifications of the protein 
synthesis, especially synthesis of albumin. Also, IL-1 con-
tributes to an increased synthesis of alpha 2-macroglob-
uline, an important factor in the evolution of the hepatic 
fibrosis. In viral hepatitis the Kupfer cells get involved into 
the IL-1 synthesis and secretion, via which they influence 
the hepatic regeneration. Along with the increase of the 
serum viral load, also an increase of IL-10 is registered in 
persons with VHC, it acting as an important inhibitor of 
IFN alpha (consequently decreasing the IFN alpha level, 
thing also identified in our study).
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Recent investigations demonstrate that AgHBcor and 
AgHBe stimulate the secretion of IL 10 by T cells and 
monocytes. Excessive production of IL-10 can modulate 
the antiviral response in HBV infection, contributing to 
the establishment of a protection against severe injuries 
and viral persistence. At the same time the HbeAg also rep-
resents a promoter of the IL-1 secretion by stimulating the 
IL-1RacP (receptor accessory for the IL-1 protein).
It is necessary to mention that multiple hepatological 
studies highlight the role of IL-10 in the suppression of the 
hepatic fibrosis, diminishing, in such a way, the activity of 
macrophages in their capacity of antigen-presenting and 
cytokine-producing cell. An opinion has been put forward, 
according to which the malady length is smaller in patients 
with HCVC and HCVB, in case of which increased levels 
of IL-1 and IFN gamma, and reduced levels of IL-10 have 
been registered. Under the influence of VHC and VHB, 
along with the process development in the hepatic tissue, 
the IL-1 level undergoes a gradual decrease and immuno-
deficiency arises, while the IFN gamma and IL-10 show an 
increase. Investigation of the level of cytokines in patients 
included in our study has also included assessment of the 
TNF alpha, which is a trigger of the antiviral response de-
velopment in B and C viral hepatitis and which correlates 
with the inflammation progress at the serum level of the 
TNF alpha. Assessment of the TNF alpha in patients in-
cluded in our study has indicated that the initial level of 
this cytokine falls into the same limits with the ones reg-
istered in patients with HCV and HBV. The in vivo and 
in vitro investigations denote that TNF alpha inhibits the 
VHB replication via the acceleration of the VHB mRNA 
degradation mechanism. Additionally, AgHBcor is sensi-
ble to TNF alpha, IFN gamma, IFN alpha. Abbas Z et al. in 
their study in 2005 specify that in chronic C hepatitis high 
levels of cytokines are registered: IL-2, TNF alpha, IFN al-
pha. In his turn Mamaev C.N. (Russia, 2006) indicates to a 
high concentration of TNF alpha and IL-4 in patients with 
chronic hepatitis, compared to persons from the control 
group. Also in this study a veridical correlation between 
TNF alpha and IL-4 with ALT, AST and with the hepatic 
morphological characteristics (histologic activity index) 
has been stated. In his research Tokmalev A.K. (Russia, 
2006) indicates high levels of TNF and IL2 in patients with 
chronic C hepatitis (91 persons), which diminish after an 
antiviral therapy with interferon. 
In our case, a similar increase of TNF alpha concentra-
tion took place in the two groups of patients following the 
administration of the therapeutic therapy with BioR.
Consequently, stimulation of the IL-10 TNF alpha pro-
duction possibly represents one of the key mechanisms of 
the antiviral activity of BioR. This gives us grounds to rec-
ommend it to persons with viral hepatitis. According to 
our data BioR gets involved into the immune mechanisms 
at the basis of the B and C chronic hepatitis evolution and 
causes a modulation of pro- and ante- inflammatory cy-
tokines, regulating in such a way their secretion by the Th1 
and Th2 lymphocytes, monocytes. 
Conclusions:
1. efficiency of the BioR preparate is proved by the 
amelioration of the haematological picture (increase 
of Hb, lymphocytes) in patients with chronic C hepa-
titis;
2. the BioR preparate is recommended for the thera-
peutic administration to patients  with viral chronic 
B and C hepatitis, characterised both by increased 
and by normal transaminases;
3. amelioration of the hepatic synthesis, expressed by 
an increase of the albumin level, speaks in favour of 
use of the BioR preparate in the HBV and HCV treat-
ment;
4. a visible diminution of the  cholestasis syndrome 
takes place in patients with HBV and HCV that have 
been subjected to the therapy with the BioR prepa-
rate;
5. increase of the level of pro-inflammatory cytokines 
(IL-1, TNF alpha) in patients with HBV and HCV 
that have been subjected to the therapy with the BioR 
preparate, indicates to an immunoregulatory activity 
of this preparate;
6. there is an increase of the anti- inflammatory cy-
tokines (IL-10) under the action of the BioR prepa-
rate in patients with HBV and HCV, fact which indi-
cated to the immunomodulation effect of the antivi-
ral response;
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